Clinical Trial: A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants

U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07015398) titled 'A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants' on June 03.

Brief Summary: The primary purpose of this study is to evaluate the effect of NAL ER on the steady-state pharmacokinetics (PK) of pirfenidone or nintedanib and the effect of pirfenidone or nintedanib on the steady-state PK of NAL ER in healthy participants.

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Healthy Participants

Intervention: DRUG: NAL ER

Oral tablets

DRUG: Pirfenidone

Oral tablets

DRUG: Nintedanib

Oral capsules

Recruitment Status: NOT_YE...